Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
The purpose of this study is to see if the combination of 177Lu-girentuximab and nivolumab is a safe and effective treatment for advanced clear cell renal cell carcinoma/ccRCC that has the CAIX protein.
Clear Cell Renal Cell Carcinoma|Kidney Cancer|Advanced Renal Cell Carcinoma
DRUG: 177Lu-labeled-girentuximab|DRUG: Nivolumab|DIAGNOSTIC_TEST: 89Zr-girentuximab PET/CT|DIAGNOSTIC_TEST: 177Lu whole body (WB) planar and SPECT/CT scans
Maximal tolerated dose (MTD) of 177Lu-girentuximab, To determine the maximal tolerated dose (MTD) of 177Lu-girentuximab when given in combination with nivolumab (safety lead-in), 24 (+/- 2) weeks|Overall Response Rate/ORR, efficacy of the combination at the MTD of 177Lu-labelled girentuximab in patients with advanced ccRCC as assessed by best ORR by 24 (+/- 2) weeks by Response Evaluation Criteria In Solid Tumors (RECIST v1.1)., 24 (+/- 2) weeks
The purpose of this study is to see if the combination of 177Lu-girentuximab and nivolumab is a safe and effective treatment for advanced clear cell renal cell carcinoma/ccRCC that has the CAIX protein.